Effect of Thyroxine and Thyrotropin on Bone Mineral Density in Postmenopausal Women: A Systematic Review

Prakar Poudel 1, Roopa Chalasani 1, Mastiyage R. Goonathilake 1, Sara Waqar 1, Sheeba George 1, Wilford Jean-Baptiste 1, Amina Yusuf Ali 1, Bithaiah Inyang 1, Feeba Sam Koshy 1, Kitty George 1, Lubna Mohammed 1

Abstract

The effect of thyroid hormones on bone mineral density in postmenopausal women has been reported but is not completely established. To better understand this relationship, this systematic review of the reported association, differences, and effects of thyroxine and/or thyrotropin levels on bone mineral density was conducted. An electronic literature search was conducted on MEDLINE, PMC, Google Scholar, Cochrane Library, and Science Direct from inception to April 2022; 20 studies were identified which include five quasi-experimental studies, three community cohort studies, and 12 hospital-based cross-sectional studies. Following an extensive evaluation, it was difficult to conclusively determine the association or effect of thyroxine or thyrotropin levels on bone mineral density in postmenopausal women. It is therefore suggested to conduct additional non-randomized or randomized control studies on this topic for the benefit of postmenopausal women. Particular attention should be given to the adjustment of age, body mass index, smoking status, alcohol consumption, and dietary calcium in future research on this topic for rigorous analysis.

Introduction And Background

Menopause is the mark of the end years of reproduction in a woman’s life when she naturally stops having menstruations. It happens when the ovaries stop making the estrogen hormone, which is responsible for her monthly menstrual period [1]. The National Institute of Aging has defined menopause as a time point at 12 months after a woman’s last period. The transitory period leading to this point of menopause is called peri-menopause. The natural average age of menopause is 51 years unless there is no pathological condition. However, it varies from ages 45 to 55 years. These variations may due to numerous lifestyle factors, exposure to hormones, genetics, race, ethnicity, and other factors [2].

A gradual loss of bone mass, usually after 50 years of age, is the natural phenomenon of the aging process. A general pattern of bone loss in aging, with the parameter of areal bone mineral density (BMD) assessed by dual-energy x-ray absorptiometry (DXA), had been well documented over many years [3]. Areal BMD is expressed in grams of calcium per square centimeter (g/cm²), which can also be plotted in terms of standard deviations of T and Z scores. T score denotes the standard deviation (SD) of measurement compared with the healthy young (age 20–40 years) population, whereas the Z score denotes the standard deviation of measurement compared with the population adjusted for age, weight, and ethnic group. According to the WHO criteria, a T-score < -2.5 SD was defined as osteoporosis, between -2.5 and -1.0 SD as osteopenia, and > -1.0 SD as normal [4].

Women lose BMD more rapidly than men, especially with the onset of menopause. The loss is more noticeable in trabecular bone rather than in the cortical bone of the lumbar spine (LS), femoral neck(FN), pelvis/total hip(TH), and ultra distal wrist [3]. During the first eight years of postmenopausal time frame, the accelerated bone loss is due to bone resorption being favored against the bone formation process [5]. The significant increase in bone mass of postmenopausal women after estrogen hormone administration depicts that estrogen is a regulator of such bone remodeling [6].

Another regulatory mechanism also exists in the hypothalamic-pituitary-thyroid axis as illustrated below in Figure 1. The stimulatory effect of thyrotrophin/thyroid-stimulating hormone (TSH) on the synthesis and release of thyroid hormones (thyroxine/T4 and triiodothyronine/T3) from the thyroid gland is regulated by the counter-inhibitory effect of T3 and T4 on the pituitary gland to release TSH. Therefore, in regard to primary thyroid disorders that are more common, TSH level has a logarithmic inverse relationship to free T4 (T4) and T3 level [7].

References

1. Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA

Corresponding author: Prakar Poudel, prakarpdl2020@gmail.com

How to cite this article

Poudel P, Chalasani R, Goonathilake M R, et al. (June 26, 2022) Effect of Thyroxine and Thyrotropin on Bone Mineral Density in Postmenopausal Women: A Systematic Review. Cureus 14(6): e26353. DOI 10.7759/cureus.26353

Categories: Endocrinology/Diabetes/Metabolism, Family/General Practice, Internal Medicine

Keywords: postmenopausal women, bone mineral density, thyrotropin, thyroxine, dexa
FIGURE 1: Hypothalamic-pituitary-thyroid axis.

TRH: thyrotropin-releasing hormone; TSH: thyroid-stimulating hormone; T4: thyroxine; T3: triiodothyronine; (+): stimulatory effect; (–): inhibitory effect.

Figure created by the first author with BioRender.com.

In addition, thyroid hormones and TSH levels are also altered with increasing age in postmenopausal women [8]. An extremely high level of thyroid hormones is a well-recognized risk factor for low BMD [9,10]. However, the effects of subclinical hyperthyroidism or hypothyroidism on BMD remain unclear. Furthermore, the influences of T4 replacement and suppressive therapy on BMD remain questionable. The association of TSH level with BMD had also been reported [11-13], along with discrepant results from some researchers [14,15].

The lifetime risk of hip and vertebral fractures in postmenopausal women is high with low BMD [4]. With such risk, the conflicting data on the bony effect of thyroid hormones or TSH brings challenges during titration of levothyroxine dose in replacement or suppressive therapy and also monitoring the bone status of the patients on hormone replacement therapy. There is no consensus demonstrating the effect of T4 levels of either endogenous or exogenous sources, or TSH levels on BMD in postmenopausal women. Therefore, this systematic review was conducted to examine the evidence on the correlation or effect of T4 level and/or TSH level on BMD in postmenopausal women.

Review

Methods

This systematic review was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines.

Eligibility Criteria

The studies were selected based on the participants, exposure or intervention, and outcomes or effect (PIO) elements with or without a comparison group (C). Participants were postmenopausal women, exposure or intervention with thyroxine/TSH level, comparison with euthyroid women or within the subgroups, and effect measured in BMD. Table 1 and Table 2 enlist inclusion criteria and exclusion criteria respectively.
Inclusion criteria

| Articles with available DOI number published in English language or any other languages that could be retrieved using automatic Google translate |
| Reports with postmenopausal female participants with a mean or median age of 45 years and above |
| Reports with available measured levels of exogenous or endogenous thyroid hormones or TSH irrespective of treatment indications or disease pathology of study participants |
| Reports with available BMD data of lumbar spine or femoral neck or hip bone or lower arm irrespective of whether this is the endpoint or not |

TABLE 1: Inclusion criteria checklist.
DOI: digital object identifier; TSH: thyroid-stimulating hormone; BMD: bone mineral density.

Exclusion criteria

| Case report, case series, editorials, opinions, views and commentaries, literature review, conference proceedings, poster presentations, and any report with incomplete peer review. |
| Reports with study participants using oral contraceptives, menopausal hormonal therapy, and medications that might affect bone metabolism (calcium, Vitamin D or analogues, bisphosphonates, SERMs, diuretics, lithium, corticosteroids, antidepressants, or antipsychotics) |
| Reports with study participants having CKD, ESRD, ileal resection, rheumatic bone diseases |

TABLE 2: Exclusion criteria checklist.
SERM: selective estrogen receptor modulator; CKD: chronic kidney disease; ESRD: end-stage renal disease.

Search Strategy and Databases

The search was performed systematically with the use of keywords, Medical Subject Headings (Mesh) search blocks with BOOLEAN operators, wherever required, along with available filters using PubMed, PubMed Central (PMC), Cochrane Library, Google Scholar, and Science Direct databases. The last date of the search for all databases was April 3, 2022. The search strategy used in the process is listed in Table 3.
Selection Process

There were a total of 614 records from all five databases using various search strategies across databases. 80 duplicate records were removed using EndNote X9 version and manually. The remaining 534 records were initially screened based on the titles and abstracts by the first author without any automation tool, excluding irrelevant studies. Hence, 190 reports were sought for retrieval of free full text; 70 reports were assessed for eligibility, and 46 articles did not fulfill the inclusion and exclusion criteria and were thus excluded. The complete PRISMA flow diagram of this review is shown in Figure 2.
Finally, a quality assessment for each article was done, and those studies with a score at or greater than 70% were accepted in the review. We used the following quality assessment tools: Cochrane Risk of Bias Tool for randomized control trial, JBI appraisal checklist for quasi-experimental study, Newcastle Ottawa scales for case-control and cohort study, and AXIS tool for cross-sectional study. The final studies to be included were decided by the first and second authors working independently for quality assessment of articles. The decision of the third author was sought in case of disagreement.

Data Synthesis

The outcome variables of interest were BMD or T score or Z score of the lumbar spine (LS), femoral neck (FN), total hip (TH), or trochanter. The key information of the selected studies was organized on a data sheet with the name of the first author, publication year, country, study design, study settings, study participants, comparison groups, thyroid disorder or other comorbidities, fT4 reference level, TSH reference level, the outcome measure of interest, statistical analysis and conclusion. All the relevant data from the included studies were extracted to an excel sheet form (Microsoft Corporation, 2010 version) by the first reviewer. No automated tool was used for the data extraction process.

Results

Quality Screening and Bias Risk

The screened 70 reports were first assessed using the inclusion and exclusion criteria. Then, the obtained screened reports were further assessed for their quality and risk of bias using appropriate tools which are well summarized in Tables 4-5. Only those reports with allotted scores at or greater than 70% were finally included in the review.
### TABLE 4: Assessment of quasi-experimental studies with JBI questionnaire tool of Figure 4.

JBI- Joanna Briggs Institute.

Y- Yes, N- No, UC- Unclear; Scores allotted: Y= 2, N= 0, UC= 1.

| Studies                  | Question number | Total allotted scores |
|--------------------------|-----------------|-----------------------|
|                          | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   | Percentage calculated |
| Polovina S et al. [16]   | Y   | N   | Y   | UA  | Y   | Y   | Y   | Y   | Y   | 75%                     |
| Daniz HC et al. [17]     | Y   | Y   | N   | Y   | Y   | UA  | Y   | Y   | Y   | 72.50%                  |
| Vendrami C et al. [18]   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 90%                      |
| Ding B et al. [19]       | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 80.00%                  |
| Moon JH et al. [20]      | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 82.50%                  |
| Ali TM et al. [21]       | Y   | Y   | N   | UA  | Y   | N   | Y   | Y   | Y   | 72.50%                  |
| Raverter JL et al. [22]  | Y   | Y   | Y   | Y   | Y   | N   | Y   | Y   | Y   | 77.50%                  |
| Hoeg A et al. [23]       | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 75%                      |
| Murphy E et al. [24]     | Y   | Y   | UA  | Y   | Y   | N   | Y   | Y   | Y   | 72.50%                  |
| Chen CY et al. [25]      | Y   | Y   | UA  | Y   | Y   | Y   | Y   | Y   | Y   | 77.50%                  |
| Park SH et al. [26]      | Y   | Y   | UA  | Y   | Y   | Y   | Y   | Y   | UA  | 75.00%                  |
| Liu C et al. [27]        | Y   | Y   | UA  | Y   | Y   | N   | Y   | Y   | Y   | 72.50%                  |
| Toivonen J et al. [28]   | Y   | Y   | Y   | Y   | N   | UA  | Y   | Y   | Y   | 70%                      |
| Rosario PW et al. [29]   | Y   | Y   | Y   | Y   | N   | N   | Y   | Y   | N   | 72.50%                  |
| De Mingo ML et al. [30]  | Y   | Y   | N   | Y   | Y   | N   | Y   | Y   | Y   | 80%                      |
| Baldini M et al. [31]    | Y   | Y   | N   | Y   | Y   | Y   | Y   | Y   | N   | 65.00%                  |
| Arnautovic HA et al. [32]| Y   | Y   | N   | Y   | Y   | Y   | UA  | Y   | N   | 57.50%                  |
| Begić A et al. [33]      | Y   | Y   | N   | N   | UA  | Y   | Y   | Y   | N   | 65.00%                  |

### TABLE 5: Assessment of cross-sectional studies with AXIS questionnaire tool of Figure 3.

AXIS: appraisal tool for cross-sectional studies; Y- yes; N- No; UA- unsure/unanswered; scores allotted: Y= 2, N= 0, UA= 1.

Note: For question number 13 and 19: N=2, Y= 0, UA=1.
After quality screening and bias risk assessment, the final 20 studies and reports were included in the review. The relevant extracted information from those final included studies and reports are enlisted in Tables 6–8. The tables are categorized on the basis of study type and study setting.

### Studies

| Publications | Year | Country of study | Euthyroid study participants | Reference values | Outcome: BMD, T score, and Z score | Statistical analysis | Adjustment for analysis | Conclusion |
|--------------|------|------------------|------------------------------|------------------|-----------------------------------|---------------------|------------------------|------------|
| Vendrami C et al. [18] | 2021 | Switzerland | 533 | Not available | 12.22 | 0.27–4.20 | LS, FN, Hip T-score | Spearman correlation and linear regression | Age, BMI, duration of Menopause | No association between fT4 and TSH with LS-BMD, FN BMD, hip BMD |
| Hwang A et al. [23] | 2012 | Europe | 1140 | 2.11–5.23 | 9.07–16.62 | 0.13–3.46 | LS-BMD, Hip BMD | Stepwise regression | Age, BMI, smoking, Selenium | Association persist between higher fT4 level and hip BMD |
| Murphy E et al. [24] | 2010 | European countries | 593 | 2.16–5.29 | 9.15–16.99 | 0.13–3.46 | LS-BMD, Hip BMD | Stepwise regression | Age, BMI, smoking | Inverse correlation between hip BMD and fT4 level, No relation between TSH level and BMD level |

### TABLE 6: Community-based cross-sectional studies

BMI: body mass index; fT3: free triiodothyronine; fT4: free thyroxine; TSH: thyroid-stimulating hormone; BMD: bone mineral density; LS: lumbar spine; FN: femoral neck.
| Studies | Publication year | Country of study | Study participant | Comparison group | Thyroid disorders and comorbidities | Reference level | Outcome of interest | Statistical analysis | Conclusion |
|---------|-----------------|------------------|-------------------|-----------------|----------------------------------|----------------|-------------------|-------------------|------------|
| Li C et al. [27] | 2020 | China | 213 | TSH level tertile subgroup in euthyroid range | Type 2 Diabetes Mellitus | Not available | LS, FN, hip joint BMD | Mann-Whitney U test, Kruskal-Wallis test, multivariate regression analysis | Significant difference in FN and hip BMD of low TSH compared with high TSH. Positive association between BMD of FN and hip joint and TSH |
| Ali TM et al. [28] | 2020 | Iraq | 160 | Hyperthyroid, hypothyroid, euthyroid | Unavailable | 9-30 | 0.35-5 | LS-BMD, Left femur BMD | Binary Logistic Regression | Hypothyroidism was the significant risk factor that causes osteoporosis with an OR of 2.89 (1.15-7.24) |
| De Marco ML et al. [29] | 2018 | Spain | 84 | Baseline self-control | Thyroidectomy for DTC with TSH suppression | Not available | Not applicable | LS-BMD | Multivariable linear regression | Serum TSH level and duration of TSH suppression are not a predictive variable of LS-BMD |
| Chen CY et al. [30] | 2018 | Taiwan | Levothyroxine treatment group=52 | Baseline self-control | Nonfunctioning benign nodular thyroid goiter | 6.1-18.1 | 0.35-5 | LS-BMD, FN-BMD, TH-BMD | Paired t test | After two years, no significant difference observed in BMD of the treatment group |
| Ding B et al. [31] | 2016 | China | 1097 | Normal BMD, osteopenia, osteoporosis | Unavailable | 7.8-15.7 | 0.5 | Not applicable | ANOVA, multiple logistic, and linear regression | Significant differences in TSH levels among the 3 groups |
| Moore JH et al. [32] | 2018 | South Korea | 273 | None | Thyroidectomy for DTC with TSH suppression | 11.4-23 | 0.3-4 | LS BMD | Pearson correlation | No correlation between T4 and TSH with LS-BMD |
| Rosato PW et al. [33] | 2016 | Brazil | Study group=60, comparison group=60 | Subclinical hyperthyroid, euthyroid | Autonomous nodular thyroid disease | 10-33 | 0.4-4 | LS, FN-BMD | Father's exact, Mann-Whitney U test | No significant difference between the two groups |
| Pobrona S et al. [34] | 2015 | Serbia | Study group=27, comparison group=61 | Subclinical hyperthyroid, euthyroid | Autimmune thyroiditis, toxic goiter | 9-19.1 | 0.35-4.04 | LS and FN-BMD, T-score | Inverse Mann-Whitney U test, Linear regression | Significant association between TSH, T4, and Fh BMD |
| Donçi HC et al. [35] | 2014 | Turkey | 261 | Hyperthyroid, hypothyroid, autoimmune thyroiditis, euthyroid | Hyperthyroidism, hypothyroidism, Autimmune thyroiditis | 11.5-21.8 | 0.27-4.2 | LS, FN-BMD, T-score | ANOVA | No significant difference in BMD observed among the groups |
| Park SH et al. [36] | 2008 | South Korea | Study group=30, comparison group=40 | TSH suppressive group=13.35 and non-suppressive group | Thyroidectomy for DTC with TSH suppression | Not available | Not applicable | LS-BMD, FN-BMD, T-score, Z-score | Unpaired t test | No significant difference observed between these two groups |
| Reverter JL et al. [37] | 2005 | Spain | 88 | Levothyroxine suppressive therapy, euthyroid | Thyroidectomy for DTC with TSH suppression | 10.3-24.45 | 0.3-5.5 | LS-BMD, FN-BMD, T-score, and Z-score | t test, Chi-square test | No difference was observed in BMD, T, and Z score between the therapy group and the control |
| Toivonen J et al. [38] | 1988 | Finland | 20 patients and 12 comparison | TSH suppressive group and euthyroid group | Thyroidectomy for DTC with TSH suppression | 8-24 | 0.50-4.1 | LS, FN, Wani's triangle BMD | Two-sided t test | No significant difference between the two groups |

**TABLE 7: Hospital-based cross-sectional studies.**

DTC: differentiated thyroid cancer; OD: odds ratio; ITA: free thyroxine; TSH: thyroid-stimulating hormone; BMD: bone mineral density; LS: lumbar spine; FN: femoral neck; TH: total hip; ANOVA: analysis of variance.
Table 8: Hospital-based quasi-experimental studies.

| Studies                  | Publication year | Country of study | Study participants | Thyroid disorders or other comorbidities | Reference values | Follow-up time | Outcome of interest | Statistical analysis                        | Conclusion                                                                 |
|--------------------------|------------------|------------------|--------------------|------------------------------------------|------------------|----------------|--------------------|---------------------------------------------|-----------------------------------------------------------------------------|
| Chung CW et al. [36]     | 2021             | South Korea      | 164                | Thyroidectomy for DTC with TSH suppression | TSH suppressive groups based on level (mean <1 mIU/L and >1 mIU/L) | 11.45-23        | 2 years and 4 years | LS-BMD | t-test | No significant difference was observed between these two groups at 2 and 4 years of suppression |
| Zhang P et al. [37]      | 2018             | China            | 225                | Thyroidectomy for DTC with TSH suppression | TSH suppressive groups based on level (mean <0.3 mIU/L and >0.3 as control) Baseline self-control group | 6.6-24.8        | 6, 12, 24 months   | LS-BMD | Paired and unpaired t-test, Pearson analysis | No significant difference between two different TSH level groups, no difference after treatment in 6, 12, 24 months compared with baseline in both TSH level groups, and no correlation between fT4, fT3, and BMD level |
| Yoshihara A et al. [38]  | 2016             | Japan            | 42                 | Graves’ disease Baseline pre and post treatment self-control group | Not available | 10.3-20.5               | 9,12,18,24 months | LS-BMD, FN-BMD, DR-BMD, T-score, Z score | Significant differences were observed in FN-BMD from pre-treatment baseline after 12 months of achieving euthyroid state, Significant increase in BMDFN after 6 months of achieving euthyroid state |
| La Vignera S et al. [39] | 2018             | Italy            | 110                | Non-functioning nodular benign thyroid disease Levothyroxine therapy and no therapy groups Pre and post-exposure self-control group | Not available | 0.49-4.67 | 2 years | LS-BMD | Paired and unpaired t-test | After two years, suppressive levothyroxine therapy decreases LS-BMD. |
| Kung AW et al. [34]      | 1995             | China            | 15                 | Thyroidectomy for DTC with TSH suppression Baseline pre and post-exposure self-control group (TSH maintained below <0.03 throughout the study) | Not available | Not applicable | 2 years | LS-BMD | T-test | Significant bone loss at LS 5%, FN -6.7%, trochanter-4.7%, Ward’s triangle of hip-0.9% |

**Discussion**

In this systematic review, we found that three community cohort studies were carried out among the population of European countries and concluded with mixed results. One of the cohort studies demonstrated that both fT4 and TSH levels within the euthyroid range are not associated with BMD of LS, FN, and hip [18]. However, another six-year cohort study demonstrated an inverse relationship between hip BMD and fT4 levels across the normal fT4 concentration range. This association was more evident in hip BMD at the beginning and after six years of follow-up. While the BMD of the lumbar spine was correlated with the fT4 level, only at the baseline of the study. The TSH had no relationship with the BMD [24]. Similarly, a large cohort study in the European population observed that a negative association persists between fT4 level and hip BMD [23]. These three cohort population studies have different reference ranges for fT4 and TSH, which could explain these discrepant results. Additionally, the adjustment for statistical analysis of alcohol consumption, duration of menopause, and smoking status was not present in every study.

Multiple hospital-based cross-sectional studies demonstrated that there was no significant difference in BMD level or T score or Z score between comparison groups with high, low, and normal fT4 and/or TSH levels [17,22,25-30]. Moreover, a study also found no significant correlation between fT4 level and TSH level with LS-BMD. There was also no difference in LS-BMD, in accordance with the duration of low TSH levels [20]. Also, another study with a baseline comparison of the TSH suppressive group showed no significant difference in BMD before and after two years of follow-up. However, the duration of TSH suppression was not adjusted in the study analysis [25].

In contrast, one study revealed a significant positive relationship between TSH level and the negative
correlation between fT4 level and FN-BMD. This relationship was even evident after the adjustment of age, BMI and smoking [16]. Likewise, another study also found that hyperthyroidism was a significant risk factor for osteoporosis with the odds of developing osteoporosis being 2.89 with a high fT4 level. However, this study was small enough to have this conclusion [21]. Also, a study demonstrated a significant difference in both FN and hip BMD between low and high TSH level groups [27]. On the other hand, one study identified a significant difference in TSH levels between osteoporosis and normal groups. This study also predicted that the odds of having osteoporosis increase with low TSH levels. Further analysis even revealed that the women with osteoporosis had significantly higher fT4 levels and lower TSH levels in comparison with osteopenia or the normal group. However, this study was cross-sectional and the percentage of women did not reach a significant difference between subclinical hyperthyroidism and hyperthyroidism, which can render these findings questionable [19]. Therefore, all of these studies signify a positive relationship between TSH level and the negative relationship of fT4 level with BMD value.

A total of five quasi-experimental studies were identified as a part of this systematic review. One of the studies concluded a significant decrement of 5%, 6.7%, and 4.7% in BMD at LS, FN, and trochanter site respectively, after keeping TSH levels below 0.05 mIU/L throughout two years of study. Although, the study participants were few [34]. Similarly, in another study, suppressive therapy that kept TSH level below 0.5 mIU/L for two years significantly reduced LS-BMD. But this finding was only apparent if BMI and smoking status were not adjusted [35]. A study with a different approach also found that treating hyperthyroidism can lead to a significant increase in FN-BMD after a minimum of six months of achieving euthyroid status. But, the duration of hyperthyroid status at the beginning of the study was not adjusted [38].

Inconsistent with earlier studies, two studies indicated an opposing conclusion, however, there are still gaps in these findings. One study found no significant difference in LS-BMD relative to TSH suppression groups (below 1 mIU/L and above 1 mIU/L). No difference was observed at either two years or four years of suppression. However, the researchers of this study did not adjust the analysis for BMI and smoking status [56]. Likewise, another study also depicted that there was neither a correlation between fT4 level and BMD level nor there was a difference in BMD before and after TSH suppression for as long as two years. However, this finding could have also been biased by the inclusion of patients with lung metastasis [37].

Limitations

This systematic review was done based on available studies. Even though the inclusion criteria include studies with mean or median age of more than 45 years, some cross-sectional studies have participants with an age range starting from 40 years [16]. The discrepancy is obvious with heterogeneity in terms of genetic variations, variation among reference range of thyroid hormones level, BMD value of population, and the variation in T and Z scores due to geographical, racial, and ethnical differences [24]. The assumption that smoking, alcohol consumption, and coffee use among study participants could be confounding factors that had not been fully adjusted in multiple studies. In addition, dietary calcium intake can be difficult to monitor and maybe a confounding factor in deviating BMD outcomes [22,34]. Neither the BMI, which is an obvious factor to influence BMD [17,20,22,25,26,28,29,35,36], nor the duration of exposure to T4 level or TSH level were adjusted in multiple studies [16,19]. This review also did not extract a portion of data from a report because of the discrepancy between the statement written in the result section and the information presented in Table number 2 [19].

Conclusions

It was difficult to undoubtedly prove that T4 and TSH levels have an independent effect on BMD in postmenopausal women. Despite the demonstration of association with few studies, the overall conclusion was inconsistent and still remains questionable. Additional research must be conducted with a randomized or non-randomized controlled study design to be able to find the definitive effect. Moreover, the adjustment of age, BMI, smoking, alcohol consumption, duration of exposure, and dietary intake of calcium need to be made in studies for robust results. The clear conclusion on this topic can be beneficial for postmenopausal women while monitoring the bone status in thyroid disorders or during titration of medications that alters bone metabolism.

Appendices

Appraisal of cross-sectional studies can be seen in Figure 3.
### Appraisal of Cross-sectional Studies

| Question                                                                 | Yes | No | Don’t know/ Comment |
|--------------------------------------------------------------------------|-----|----|---------------------|
| **Introduction**                                                         |     |    |                     |
| 1  Were the aims/objectives of the study clear?                          |     |    |                     |
| **Methods**                                                              |     |    |                     |
| 2  Was the study design appropriate for the stated aim(s)?                |     |    |                     |
| 3  Was the sample size justified?                                        |     |    |                     |
| 4  Was the target/reference population clearly defined? (Is it clear who the research was about?) |     |    |                     |
| 5  Was the sample frame taken from an appropriate population base so that it closely represented the target/reference population under investigation? | | | |
| 6  Was the selection process likely to select subjects/participants that were representative of the target/reference population under investigation? | | | |
| 7  Were measures undertaken to address and categorise non-responders?     |     |    |                     |
| 8  Were the risk factor and outcome variables measured appropriate to the aims of the study? |     |    |                     |
| 9  Were the risk factor and outcome variables measured correctly using instruments/measurements that had been trialed, piloted or published previously? | | | |
| 10 Is it clear what was used to determine statistical significance and/or precision estimates? (e.g. $p$-values, confidence intervals) | | | |
| 11 Were the methods (including statistical methods) sufficiently described to enable them to be repeated? | | | |
| **Results**                                                              |     |    |                     |
| 12 Were the basic data adequately described?                              |     |    |                     |
| 13 Does the response rate raise concerns about non-response bias?         |     |    |                     |
| 14 If appropriate, was information about non-responders described?        |     |    |                     |
| 15 Were the results internally consistent?                                |     |    |                     |
| 16 Were the results presented for all the analyses described in the methods? |     |    |                     |
| **Discussion**                                                           |     |    |                     |
| 17 Were the authors' discussions and conclusions justified by the results? |     |    |                     |
| 18 Were the limitations of the study discussed?                           |     |    |                     |
| **Other**                                                                |     |    |                     |
| 19 Were there any funding sources or conflicts of interest that may affect the authors’ interpretation of the results? | | | |
| 20 Was ethical approval or consent of participants attained?              |     |    |                     |

**FIGURE 3: AXIS- Appraisal tool for cross-sectional studies.**

Figure 9 shows the Joanna Briggs Institute (JBI) checklist for quasi-experimental studies.
FIGURE 4: Joanna Briggs Institute (JBI) checklist for quasi-experimental studies.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Acknowledgements
The authors would like to acknowledge the help and suggestions from Dr. Aneeta Channar and special thanks to Dr. Hassaan Tohid for providing us with insightful guidance throughout the study process.

References

1. The menopause years. (2021). Accessed: April 14, 2022: https://www.acog.org/womens-health/faqs/the-menopause-years.
2. What is menopause?. (2021). Accessed: April 14, 2022: https://www.nia.nih.gov/health/what-menopause.
3. Clarke BL, Khonsa S: Physiology of bone loss. Radiol Clin North Am. 2010, 48:485-95. 10.1016/j.rcl.2010.02.014
4. World Health Organization: Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis: Report of a WHO Study Group [Meeting Held In Rome From 22 to 25 June 1992]. WHO Office of Publications, Geneva, Switzerland; 1994. https://apps.who.int/iris/bitstream/handle/10665/39142/WHO_TRS_845_eng.pdf.
5. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD: Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996, 11:537-49. 10.1002/jbmr.560110307
6. Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC: Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet. 1976, 307:1038-41. 10.1016/s0140-6736(76)92217-0
7. Ortega-Carvalho TM, Chiamolora MJ, Pazoz-Moura CC, Wonsidorski FE: Hypothyalousm-pituitary-thyroid axis. Comp Physiol. 2016, 6:1387-428. 10.1016/j.cphys.2016.11.007
8. Waring AC, Arnold AM, Newman AB, Buzkova P, Hirsch C, Cappola AR: Longitudinal changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars study. J Clin Endocrinol Metab. 2012, 97:3944-50. 10.1210/jc.2012-2481
9. Vestergaard P, Mosekilde L: Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid. 2002, 12:411-9. 10.1089/105072502760045505
10. Vestergaard P, Mosekilde L: Hyperthyroidism, bone mineral, and fracture risk—a meta-analysis. Thyroid. 2005, 15:585-95. 10.1089/10507250532258854
11. Mazzotti G, Porcelli T, Patelli I, Vescovi PP, Giustina A: Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density. Bone. 2010, 46:747-51. 10.1016/j.bone.2009.10.051
12. Bauer DC, Ettinger B, Nevitt MC, Stone KL: Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med. 2001, 134:561-8. 10.7326/0003-4819-134-7-20010405-00009
13. Morris MS: The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women. Bone. 2007, 40:1128-34. 10.1016/j.bone.2006.12.001
14. Mendoça Monteiro de Barros G, Madeira M, Vieira Neto L, et al.: Bone mineral density and bone microarchitectue after long-term suppressive levothyroxine treatment of differentiated thyroid carcinoma in young adult patients. J Bone Miner Metab. 2016, 34:417-21. 10.1007/s00774-015-0680-4
15. Garin MC, Arnold AM, Lee JS, Robbina J, Cappolla AR: Subclinical thyroid dysfunction and hip fracture and bone mineral density in older adults: the cardiovascular health study. J Clin Endocrinol Metab. 2014, 99:2657-64. 10.1210/jc.2014-1015
16. Polovina S, Mićić D, Mićić D, Mićić N, Popović V: The Fracture Risk Assessment Tool (FRAX score) in subclinical hyperthyroidism. Vojnosanit Pregl. 2015, 72:510-6. 10.2298/vsp1306510p
17. Deniz HC, Keskin HL, Seçen EI, Aşçay GF, Üstüner I, Avşar AF: Thyroid dysfunction does not affect the bone mineral density in postmenopausal women. J Clin Anal Med. 2014, 5:25-8. 10.4328/JCAM.1197
18. Vendrami C, Marques-Vidal P, González Rodriguez E, Hans D, Waerger G, Lamy O: Thyroid-stimulating hormone is associated with trabecular bone score and 5-year incident fracture risk in euthyroid postmenopausal women: the OsteoLaus cohort. Osteoporos Int. 2022, 33:195-204. 10.1007/s00198-021-06081-4
19. Ding B, Zhang Y, Li Q, et al.: Low thyroid stimulating hormone levels are associated with low bone mineral density in femoral neck in elderly women. Arch Med Res. 2016, 47:530-4. 10.1016/j.arcmed.2016.07.009
20. Moon JH, Kim KY, Oh TJ, et al.: The effect of TSH suppression on vertebral trabecular bone scores in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2017, 102:78-85. 10.1210/jc.2016-2740
21. Ali TM, Al-Izaiz FI: The correlation between thyroid function status and bone mineral density among postmenopausal women. Indian J Public Health Res Dev. 2020, 11:234-40. 10.37506/ijphrd.v11i9.11014
22. Reverter JL, Holgado S, Alonso N, Salinas I, Granada ML, Sammarti A: Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma. Endocr Relat Cancer. 2005, 12:975-81. 10.1677/erc.1.01072
23. Hoen A, Gogakos A, Murphy E, et al.: Bone turnover and bone mineral density are independently related to selenium status in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab. 2012, 97:4061-70. 10.1210/jc.2012-2121
24. Murphy E, Glier CC, Reid DM, Felsenberg D, Roux C, Eastell R, Williams GR: Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab. 2010, 95:5173-81. 10.1210/jc.2009-2620
25. Chen CY, Chen ST, Huang BY, Hwang JS, Lin JD, Liu FH: The effect of suppressive thyroxine therapy in nodular goiter in postmenopausal women and 2 year’s bone mineral density change. Endocr J. 2018, 65:1101-9. 10.1507/endocrj.EJ18-0125
26. Park SH, Lee J, Choi SY, Soh EY: The bone mineral density and bone metabolism of patients with differentiated thyroid carcinoma and who are receiving long-term TSH suppressive therapy. J Endocr Surg.
27. Liu C, Pan J, Wen S, et al.: Low TSH levels within euthyroid range could play a negative role on bone mineral density in postmenopausal women with type 2 diabetes. Diabetes Metab Syndr Obes. 2021, 14:2549-55. 10.16956/kjes.2008.8.2.89

28. Toivonen J, Tähtelä R, Laitinen K, Risteli J, Välimäki MJ: Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy. Eur J Endocrinol. 1998, 138:667-73. 10.1530/eje.0.1380667

29. Rosario PW, Carvalho M, Calsolari MR: Symptoms of thyrotoxicosis, bone metabolism and occult atrial fibrillation in older women with mild endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf). 2016, 85:132-6. 10.1111/cen.12979

30. De Mingo Dominguez ML, Guadalix Iglesias S, Martin-Arriscado Arroba C, et al.: Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy. Endocrine. 2018, 62:166-73. 10.1007/s12020-018-1671-8

31. Baldini M, Gallazzi M, Orsatti A, Fossati S, Leopardi P, Cantalamessa L: Treatment of benign nodular goitre with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size. J Intern Med. 2002, 251:407-14. 10.1111/j.1365-2796.2002.00977.x

32. Arnautovic-Halimic A, Begić A, Ahed-Jesenkovic D: Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy. Endocrine. 2018, 62:166-73. 10.1007/s12020-018-1671-8

33. Begić A, Begić A, Arnautović-Halimić A: Influence of thyroid hormones on bone density. Med Glas (Zenica). 2020, 17:35-40. 10.17392/1056-20

34. Kung AW, Yeung SS: Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab. 1996, 81:1232-6. 10.1210/jcem.81.3.8772604

35. La Vignera S, Condorelli RA, Vicari E, Nicoletti C, Calogero AE: Bone demineralization in postmenopausal women: role of anamnestic risk factors. Int J Endocrinol. 2012, 2012:837187. 10.1155/2012/837187

36. Chung CW, Choi HS, Kwon SH, Park YJ, Park DJ, Ahn HY, Cho SW: Measurements of bone health after thyroid-stimulating suppression therapy in postmenopausal women with differentiated thyroid carcinoma: bone mineral density versus the trabecular bone score. J Clin Med. 2021, 10:1964. 10.3390/jcm10091964

37. Zhang P, Xi H, Yan R: Effects of thyrotropin suppression on lumbar bone mineral density in postmenopausal women with differentiated thyroid carcinoma. Onco Targets Ther. 2018, 11:6687-92. 10.2147/OTT.S172182

38. Yoshiihara A, Yoshimura Noh J, Mukasa K, et al.: The characteristics of osteoporotic patients in Graves’ disease patients newly diagnosed after menopause: a prospective observational study. Endocr J. 2016, 63:1113-22. 10.1507/endocrj.EJ16-0261

39. Rosario PW: Radioiodine therapy in elderly patients with subclinical hyperthyroidism due to non-voluminous nodular goiter and its effect on bone metabolism. Arq Bras Endocrinol Metabol. 2013, 57:144-7. 10.1590/s0004-27552013000200008